Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Blood immunoreactive trypsinogen concentrations are genetically determined in healthy and cystic fibrosis newborns.

Acta paediatrica (Oslo, Norway : 1992) - 1 Mar 1999

Lecoq I, Brouard J, Laroche D, Férec C, Travert G

Abstract excerpt

Newborns with cystic fibrosis (CF) have increased blood immunoreactive trypsinogen concentrations. When screening for CF in the newborn by immunoreactive trypsinogen measurement, an abnormally high proportion of healthy deltaF508 carriers is found among false-positive neonates, suggesting that a relationship could exist between immunoreactive trypsinogen concentration at birth and the genetic status. Therefore,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to Genetic Carrier Screening

Share to Heterozygote

Share to Homozygote

Share to Neonatal Screening

Share to Trypsinogen

Source

Identifiers

PMID: 10229049
DOI: 10.1080/08035259950170141

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Blood immunoreactive trypsinogen concentrations are genetically determined in healthy and cystic fibrosis newborns.PMID 10229049Read ↗

Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers.Semantic proximity Read ↗

Susceptibility haplotypes in non-cystic fibrosis newborns with elevated immunoreactive trypsinogenSemantic proximity Read ↗

Does cystic fibrosis neonatal screening detect atypical CF forms? Extended genetic characterization and 4-year clinical follow-up.Semantic proximity Read ↗

The Impact of the CFTR Gene Discovery on Cystic Fibrosis Diagnosis, Counseling, and Preventive Therapy.Semantic proximity Read ↗

Cystic fibrosis identified by neonatal screening: incidence, genotype, and early natural history.Semantic proximity Read ↗

Neonatal screening for cystic fibrosis: result of a pilot study using both immunoreactive trypsinogen and cystic fibrosis gene mutation analyses.Semantic proximity Read ↗

Cystic fibrosis screening in neonates--measurement of immunoreactive trypsin and direct genotype analysis for delta F508 mutation.Semantic proximity Read ↗

Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening.Semantic proximity Read ↗

Retrospective study of the cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Guthrie cards from a large cohort of neonatal screening for cystic fibrosis.Semantic proximity Read ↗

Newborn cystic fibrosis screening in southeastern Mexico: Birth prevalence and novel CFTR gene variants.Semantic proximity Read ↗

Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.Semantic proximity Read ↗

Three common CFTR mutations should be included in a neonatal screening programme for cystic fibrosis in Sweden.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.